McMillan’s departure goes into effect on Oct. 20, 2023. He intends to join 3M as CFO of its Health Care business, which the company expects to spin off late this year or early next year.
President and CEO Jim Hollingshead called McMillan “a trusted partner and an excellent leader” of the company’s global finance team. He said McMillan helped to advance Insulet’s mission of improving the lives of people with diabetes.
“Wayde has helped make our company stronger and more resilient, ensuring we have the capabilities and financial strength to capitalize on the tremendous long-term growth opportunities Insulet is pursuing,” Hollingshead said in a news release. “On behalf of the board and our entire team, I thank Wayde for his many contributions and wish him well in his future endeavors.”
McMillan called it an honor to work at Insulet alongside a talented team and deliver on the company’s mission. He cited pride in the company’s accomplishments in his four-and-a-half years there.
Before joining Insulet as EVP, CFO and treasurer in March 2019, McMillan spent four years at medtech giant Medtronic. From January 2015 to February 2019, he served as CFO and VP of finance for Medtronic’s Minimally Invasive Therapies Group.
“This was a difficult personal decision for me, but also an opportunity to take on new challenges at a large medical device company at a unique time in its evolution,” McMillan said. “I am confident that Insulet is extremely well positioned to continue driving growth, profitability, and value creation, and I look forward to watching the Company’s continued success.”
Get the full story — including analysts’ reaction — at our sister site, Drug Delivery Business News.
